Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers

Background: Activation of the mTOR signaling pathway is ubiquitous in cancers and a favourable therapeutic target. However, presently approved mTOR inhibitor monotherapies have modest benefits in labeled indications while poor outcomes have been reported for mTOR inhibitor monotherapy when administe...

Descripción completa

Detalles Bibliográficos
Autores principales: Crook, Timothy, Patil, Darshana, Gaya, Andrew, Plowman, Nicholas, Limaye, Sewanti, Ranade, Anantbhushan, Bhatt, Amit, Page, Raymond, Akolkar, Dadasaheb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085687/
https://www.ncbi.nlm.nih.gov/pubmed/33935721
http://dx.doi.org/10.3389/fphar.2021.631135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085687/
https://www.ncbi.nlm.nih.gov/pubmed/33935721
http://dx.doi.org/10.3389/fphar.2021.631135

Ejemplares similares